Drug Trial Radar · NCT05305599
Different Doses of ZED1227 vs. Placebo in NAFLD
Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Actual
Start
Apr 19, 2022
Primary completion
Jun 7, 2023
Study completion Jul 5, 2023
Sponsor
- Lead sponsor
- Dr. Falk Pharma GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 20, 50, or 100 mg ZED1227 vs. placebo for the treatment of patients with NAFLD with fibrosis.
Conditions
- NAFLD
- Liver Fibrosis
Interventions
ZED1227Drug
ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change of PRO-C3 levelsTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz
Mainz, Rhineland-Palatinate, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.